A PCR Roundtable Discussion on Key Findings from the Landmark Study and it’s Relevance in Clinical Practice

Leading voices in cardiovascular healthcare engage in a dynamic conversation on the Landmark Randomised Trial, Meril is elated to present the PCR Roundtable Discussion titled 'Key Findings and Relevance in Clinical Practice'. Professors Patrick Serruys and Niels van Royen, moderated by Andreas Baumbach, convene as key figures associated with the study to share salient insights into this head-to-head comparison and assess the results that have been garnered. The Landmark study is a comparison of early outcomes of newer-generation Myval THV series with contemporary valve series in real-world individuals with severe symptomatic native aortic stenosis, a Randomised Non-Inferiority Trial.

As the Top Enroller of the Landmark Study, Professor Niels Van Royen from the Netherlands asserts that this trial has been imperative in establishing the Myval THV series’ position as non-inferior against industry benchmarks like the Evolut and Sapien THV series, further emphasizing the need for such trials to augment the Transcatheter Heart Valve technology landscape. He articulates the benefits of the Myval THV series, stating, “It's pre-crimped, it's flexible. It's getting close to a PCI procedure. So in that respect, I think they (Meril Life Sciences) did a very good job in the design of this valve.”

Professor Patrick Serruys from Ireland, Chairman of the Landmark Study, affirms that the availability of intermediate sizing with 1.5 mm increments has given an edge to the Myval THV technology. He emphasizes, “It's a small step of 1.5 mm, so that you can really address, adapt the device to the anatomy.” further adding, "[Myval THV series] technology has an edge on the others, in the sense that there are intermediate sizes, and that is very important; it's a novelty in the field."

Echoing this sentiment, Professor Andreas Baumbach from the UK, the Global PI (Principal Investigator) of the Landmark Study, elaborates on how the trial's findings on Effective Orifice Area are particularly compelling, revealing substantial advantages in terms of accurate sizing, suggesting potential implications for long-term clinical outcomes and durability. He expresses his expectations for these dynamics to translate into future benefits for patients and asserts the significance of the Myval THV series, stating, “I think this system [Myval THV Series] has arrived in clinical practice, backed by the results of our randomised trial.”

In summary, as we anticipate the outcomes from long-term follow-ups, the insights derived from the Landmark trial are poised to contribute significantly to the landscape of structural heart solutions, ensuring optimal care, and Adding More to the Life of countless patients across the globe.

Stay tuned for this remarkable conversation among celebrated thought leaders, as they share incisive insights into the key clinical findings of the Landmark Study.
We are proud to announce that the Landmark study has been published in the esteemed medical journal, The Lancet. Get an extensive look into the full manuscript through this link: https://lnkd.in/dZZHfnTq